Rabeprazole

Introduction Overview

Generic Name

rabeprazole

Brand Name

AcipHex, AcipHex Sprinkle

Dosage Form

oral delayed release tablet or capsule

Drug Class

Proton pump inhibitors

Pharmacokinetics

Absorption:
Rabeprazole is administered orally in the form of delayed-release tablets or capsules, designed to bypass the acidic environment of the stomach to ensure stability and bioavailability. Upon oral administration, it is rapidly absorbed from the small intestine with peak plasma concentrations typically reached within 3.5 to 5 hours. The delayed-release formulation protects rabeprazole from degradation in gastric acid. Absolute bioavailability is approximately 52%, reflecting first-pass metabolism. Gastric pH does not significantly affect absorption, and food intake may slightly delay the rate but not the extent of absorption. Clinical studies show that steady-state plasma concentrations are attained within three days of once-daily dosing.

Distribution:
Rabeprazole exhibits moderate distribution within the body and is approximately 96.3% bound to plasma proteins, predominantly albumin. The volume of distribution is low to moderate, indicative of limited tissue penetration. It preferentially accumulates in gastric parietal cells due to its mechanism of action, concentrating at the site of proton pumps. Because of its protein binding, rabeprazole has limited free drug concentrations to diffuse into tissues, which reduces systemic side effects. It crosses the placenta and is detectable in breast milk in minimal amounts; however, clinical data on fetotoxicity are limited.

Metabolism:
Rabeprazole undergoes extensive hepatic metabolism primarily via non-enzymatic reduction and to a lesser extent by cytochrome P450 enzymes, especially CYP2C19 and CYP3A4. Its metabolites are inactive with minimal pharmacologic effect. Genetic polymorphisms in CYP2C19 can affect the metabolism rate, leading to variations in plasma drug concentrations among different populations. Unlike some other proton pump inhibitors, rabeprazole displays less dependency on CYP2C19 metabolism, resulting in a more predictable pharmacokinetic profile across diverse populations.

Elimination:
The elimination half-life of rabeprazole is approximately 1 to 2 hours, though its duration of acid suppression is much longer due to irreversible binding to the proton pump. The drug and its metabolites are primarily excreted in the urine (approximately 90%), with a minor portion eliminated via feces. Renal excretion mainly involves inactive metabolites, and therefore rabeprazole dose adjustments are generally not required in patients with renal impairment. Hepatic impairment can affect metabolism, and close monitoring is recommended in this population. The drug’s pharmacokinetics are linear over the approved dose range, and accumulation is minimal with once-daily dosing.

Dosage Forms

Available Dosage Forms:
Rabeprazole is commercially available as oral delayed-release tablets and oral delayed-release capsules designed for sprinkle administration. The products include:
- Oral delayed release tablet: 20 mg
- Oral delayed release capsule (AcipHex Sprinkle): 5 mg and 10 mg

Dosages for Adults and Adolescents:
The usual adult dosage for gastroesophageal reflux disease (GERD) and erosive esophagitis is 20 mg orally once daily for 4 to 8 weeks. For maintenance therapy in patients with healed erosive esophagitis, the dosage may be reduced to 10 or 20 mg once daily. For Zollinger-Ellison syndrome or conditions requiring long-term acid suppression, doses may range up to 60 mg per day, divided into two doses, based on clinical response. In Helicobacter pylori eradication, rabeprazole 20 mg twice daily is combined with antibiotics, typically amoxicillin and clarithromycin.
Pediatric dosages are approved for children aged 1 year and older, with dose determination based on body weight and indication, but specific pediatric dosing should follow physician recommendations, emphasizing that AcipHex Sprinkle is not recommended for children under 1 year.

Specific Patient Populations:
In patients with hepatic impairment, dosage adjustments are advised due to decreased metabolism. Renal impairment generally does not necessitate dose modifications since renal clearance involves inactive metabolites. Geriatric patients can use standard dosing, but monitoring for adverse effects is prudent due to increased fracture risk and potential for drug interactions.

Clinical guidelines underline that rabeprazole is intended for short-term use, often restricted to 4–8 weeks for GERD and ulcer healing, but extended use under medical supervision is possible for severe acid-related disorders. The sprinkle formulation allows administration to patients who have difficulty swallowing, including pediatric and elderly populations, enhancing adherence and clinical effectiveness.

Mechanism Of Action

Rabeprazole exerts its pharmacological effect by selectively inhibiting the hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) enzyme system, commonly known as the proton pump, located on the secretory surface of gastric parietal cells. This enzymatic action is the final step in the secretion of gastric acid, making proton pumps the ideal target for effective acid suppression.

Upon absorption, rabeprazole is converted to its active sulfenamide form in the acidic environment of the secretory canaliculi of parietal cells. The activated sulfenamide then covalently binds to cysteine residues on the proton pump, leading to irreversible inactivation. By blocking the proton pumps, rabeprazole effectively inhibits basal and stimulated gastric acid secretion, resulting in a rapid and prolonged increase in gastric pH.

Unlike reversible H2 receptor antagonists, rabeprazole’s irreversible binding leads to sustained acid suppression even after plasma levels have declined, requiring de novo synthesis of proton pumps for acid secretion to resume. This prolonged action contributes to the drug’s efficacy in healing acid-related mucosal damage such as erosive esophagitis and peptic ulcers.

Compared to other proton pump inhibitors, rabeprazole has a slightly faster onset of acid suppression due to its higher pKa, which allows rapid accumulation in the acidic environment of the secretory canaliculus, thus enabling quicker activation. Clinical studies demonstrate that this property translates to more rapid symptom relief in certain patients, although overall clinical outcomes are comparable across the PPI class. Research also indicates that rabeprazole’s metabolism less depends on CYP2C19 polymorphisms, producing less interpatient variability in acid suppression levels relative to some other PPIs.

Pharmacological Actions

Potent and selective inhibition of H+/K+ ATPase proton pumps in gastric parietal cells leading to profound suppression of gastric acid secretion.
Reduction of basal and stimulated gastric acid secretion, increasing gastric pH and promoting mucosal healing.
Decreases gastric acidity, thereby reducing acid-related damage in conditions like GERD, erosive esophagitis, and peptic ulcer disease.
Exhibits a rapid onset of action due to quick conversion to active sulfenamide in acidic environment.
Irreversible binding to proton pump results in sustained acid suppression lasting beyond plasma drug concentrations.
Less dependent on cytochrome P450 CYP2C19 metabolism which reduces variability in pharmacokinetic and pharmacodynamic responses.
Used in combination therapy for Helicobacter pylori eradication by enhancing antibiotic effectiveness through acid suppression.
Improves symptoms of heartburn and acid regurgitation by limiting acid exposure to the esophageal mucosa.
Aids in lowering risk of acid aspiration during surgery by raising gastric pH.
Has minimal effect on other organ systems due to localized gastric action and high protein binding.
Demonstrates potent anti-secretory effects with once-daily dosing adequacy for most acid-related disorders.
Contributes to alleviation of pain and discomfort associated with acid-induced inflammation and mucosal injury.

Therapeutic Or Clinical Uses

Short-term treatment of gastroesophageal reflux disease (GERD) in adults and children 1 year and older.
Healing of erosive esophagitis caused by acid reflux.
Management of Zollinger-Ellison syndrome and other pathological hypersecretory conditions in adults.
Treatment and prevention of duodenal ulcers, particularly those associated with Helicobacter pylori infection.
Used in combination with antibiotics such as clarithromycin and amoxicillin for H. pylori eradication.
Prevention of acid-related damage in patients with chronic NSAID use causing gastric irritation.
Relief of heartburn symptoms related to acid reflux, though not intended for immediate heartburn relief.
Maintenance therapy post healing of erosive esophagitis to prevent recurrence.
Management of gastric acid hypersecretion in Zollinger-Ellison syndrome and multiple endocrine adenomas.
Adjunct therapy in conditions requiring reduced gastric acidity to facilitate ulcer healing.
Off-label use in treatment of Barrett’s esophagus to decrease acid exposure and mucosal damage.
Reducing gastric acidity to improve outcomes in patients undergoing upper gastrointestinal surgery.

Side Or Adverse Effects

Commonly reported adverse effects include headache, sore throat, and upper respiratory infections.
Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, gas, diarrhea, and constipation.
Potential for serious allergic reactions including hives, facial swelling, and difficulty breathing.
Serious side effects may include severe stomach pain or diarrhea that is watery or bloody indicating possible Clostridium difficile infection.
Risk of low magnesium levels presenting as muscle cramps, tremors, irregular heartbeat, or seizures with long-term use.
Development of fundic gland polyps in stomach mucosa with prolonged therapy.
Possibility of vitamin B12 deficiency after prolonged use over 3 years due to impaired absorption.
Rare reports of lupus erythematosus-like syndrome including joint pain and photosensitive rash.
Kidney problems presenting with symptoms like rash, fever, nausea, decreased urination, and swelling.
Increased risk of bone fractures of hip, wrist, or spine in patients on long-term or high-dose therapy.
Potential bleeding complications, especially in patients concurrently taking anticoagulants such as warfarin.
Headache and dizziness reported in some cases, warranting evaluation in patients with neurological symptoms.
Hypersensitivity reactions including rash and anaphylaxis reported rarely.
Elevated liver enzymes and hepatotoxicity are rare but necessitate monitoring in hepatic impairment.
Possible interference with absorption of drugs requiring acidic environment for optimal bioavailability.

Precautions

Use with caution in patients with a history of liver disease due to metabolism involving hepatic pathways.
Monitor bone health in patients on long-term therapy especially those with risk factors for osteoporosis or low bone mineral density.
Assess magnesium levels periodically during prolonged treatment to avoid hypomagnesemia.
Avoid use in patients with known hypersensitivity to rabeprazole or other proton pump inhibitors.
Not recommended for immediate relief of heartburn symptoms; inadequate for acute symptom management.
Caution in patients with lupus erythematosus, as rabeprazole may exacerbate symptoms.
Patients with renal impairment generally do not require dose adjustment, but clinical monitoring advised.
Avoid abrupt discontinuation in dependent patients without medical supervision to prevent symptom rebound.
Use during pregnancy only if clearly needed; limited human data available on fetal safety.
Breastfeeding mothers should exercise caution; limited data on excretion in milk and effects on infants.
Avoid concomitant use with rilpivirine-containing products due to contraindications.
Exercise caution in elderly patients due to increased risk of fractures and comorbidities.
Do not crush or chew tablets; capsules should be opened and contents dispersed as per instructions.
Advise patients to inform healthcare providers about use of rabeprazole prior to any diagnostic tests.
Educate patients to report any signs of allergic reactions or severe side effects immediately.

Warnings

May cause kidney problems including acute interstitial nephritis; monitor renal function regularly.
Risk of Clostridium difficile-associated diarrhea presenting as watery or bloody diarrhea; medical attention required if symptoms occur.
Potential to cause new or worsening symptoms of systemic lupus erythematosus.
Long-term use or multiple daily doses increase risk of fractures of hip, wrist, or spine due to decreased calcium absorption.
Risk of hypomagnesemia during prolonged therapy, manifesting as cardiac arrhythmias or neuromuscular symptoms.
May increase risk of fundic gland polyps with extended use.
Potential vitamin B12 deficiency following more than 3 years of treatment.
Not suitable for immediate relief of heartburn; misuse may delay accurate diagnosis of underlying cardiac conditions.
Avoid use in patients simultaneously taking rilpivirine-containing antiretroviral therapies.
Risk of bleeding is higher when used concurrently with anticoagulants such as warfarin.
Patients should be monitored for rash, joint pain, or other signs of hypersensitivity.
Patients with osteoporosis or low bone mass should consider calcium and vitamin D supplementation during treatment.
Discontinue if severe skin reactions or anaphylaxis occur.
Use caution in patients with hepatic impairment as clearance may be decreased.
Do not use in children under 1 year (AcipHex Sprinkle formulation).

Contraindication

Known hypersensitivity to rabeprazole, substituted benzimidazoles, or any proton pump inhibitors.
Concomitant use with rilpivirine-containing medicinal products (e.g., Edurant, Complera, Juluca, Odefsey) due to potential for decreased antiretroviral efficacy.
History of severe allergic or anaphylactic reaction to rabeprazole or related drugs such as esomeprazole, lansoprazole, omeprazole, or pantoprazole.
Severe hepatic impairment without appropriate medical supervision.
Use in children younger than 12 years without specific dosing recommendations.
Caution in patients with unexplained gastric malignancies until definitive diagnosis is made.
Contraindicated in patients with acute porphyrias due to unknown risk of exacerbation.
Avoid in patients with known history of fundic gland polyps related to PPI therapy.
Contraindicated in patients with previous severe adverse reaction to any proton pump inhibitor.
Do not use for immediate relief of heartburn symptoms; inappropriate use may mask serious conditions.
Avoid co-administration with agents that strongly affect gastric pH when not clinically indicated.
Patients with QT prolongation risk should be monitored carefully if combined with drugs inducing hypomagnesemia.
Hypersensitivity or idiosyncratic reactions represent absolute contraindications to continued use.
Administration is contraindicated in the absence of a clinically justified indication.
Pregnancy category decisions should guide use; avoid if fetal risk outweighs benefit.

Drug Interactions

Rabeprazole may interact with clarithromycin and amoxicillin when used concurrently for Helicobacter pylori eradication, enhancing therapeutic effect.
Concurrent use with rilpivirine-containing antiretroviral agents is contraindicated due to reduced plasma concentration and decreased efficacy of rilpivirine.
Rabeprazole can increase serum levels of digoxin by altering gastrointestinal pH and affecting absorption.
Use with methotrexate may increase serum methotrexate levels and toxicity, particularly at high doses.
Warfarin levels and anticoagulant effects may be potentiated, increasing the risk of bleeding.
May reduce absorption of drugs requiring acidic gastric environment such as ketoconazole, itraconazole, and iron salts.
Diuretic drugs, particularly thiazides and loop diuretics, when combined with rabeprazole may contribute to increased risk of hypomagnesemia.
Limited interaction with CYP450 substrates owing to less extensive CYP2C19 metabolism compared to other PPIs.
Potential interaction with clopidogrel is less significant compared to omeprazole and esomeprazole, but caution is advised.
Rabeprazole may alter the efficacy of atazanavir due to changes in gastric acidity affecting absorption.
Co-administration with drugs such as digoxin and diazepam should be monitored for altered pharmacokinetics.
May affect plasma concentrations of tacrolimus and mycophenolate, requiring monitoring in transplant patients.
Co-use with St. John’s Wort and other herbal supplements may alter metabolism and effectiveness.
Possible interactions with calcium carbonate and aluminum hydroxide antacids affecting absorption profiles.
Numerous drugs with pH-dependent solubility should be evaluated when used concomitantly.

Preparations Of The Drug

Rabeprazole is available as delayed-release tablets, commonly 20 mg strength for oral administration.
Delayed-release sprinkle capsules known as AcipHex Sprinkle, available in 5 mg and 10 mg doses, enabling administration by opening the capsule and mixing with soft food or liquids.
Packaging typically includes bottles or blister packs with detailed dosing and administration instructions.
Manufactured under strict quality controls to ensure stability in acidic gastric environment until release.
Formulated with excipients to protect active ingredient from premature degradation in the stomach.
Available under brand names including AcipHex and AcipHex Sprinkle in various countries.
Some generic formulations available conforming to pharmacopeial standards.
Formulations require proper storage away from moisture and heat to maintain delayed-release properties.
Patient-directed instructions included for sprinkle capsule administration to pediatric and dysphagic patients.
Oral dosage forms intended for once-daily administration with no crushing or chewing of tablets recommended.
Packaging includes medication guides and safety information consistent with regulatory requirements.
Products may differ slightly in inactive ingredients, necessitating patient counseling for allergies or sensitivities.
Available in prescription form only, consistent with regulatory classification.
Typically supplied in doses facilitating titration based on clinical need.
Formulations designed to enable combination therapy with antibiotics for H. pylori eradication.